The REWIND cardiovascular (CV) outcomes trial assessed the effect of dulaglutide on first major adverse cardiac event (MACE) in 9901 people with type 2 diabetes and either CV risk factors or CV disease.1
Dulaglutide significantly reduced MACE in the presence or absence of prior CV disease.1
Dulaglutide also reduced HbA1c, weight and systolic blood pressure (BP).1
How was this study conducted?
This study assessed whether the effects of dulaglutide on HbA1c, weight and systolic BP can account for its effect on MACE.
Updated mean HbA1c, weight and systolic BP were estimated as the mean of consecutive measures before the MACE outcome or study end (or censorship if no MACE outcome).
The relationship of each variable’s updated mean value and MACE was estimated.
If the relationship was significant, the effect of dulaglutide on MACE was re-estimated in a new Cox model that included dulaglutide allocation, baseline value of the variable and updated mean of the variable as time dependent covariates.
This is a highlights summary of an oral session given at the EASD 2020 Virtual Meeting and presented by:
Hertzel C. Gerstein, MD
Master University and Hamilton Health Sciences, Hamilton, Ontario, Canada
The presenting authors of the original session had no part in the creation of this conference highlights summary.
The content is produced by Infomedica. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Florian Toti, MD, the scientific editor of the program.